findmyKOL
Clinical trialNCT04592484CompletedPhase 1/PHASE2Interventional

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

SponsorCodiak BioSciencesEnrollment27Advanced Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed despite receiving standard of care treatment. CDK 002 will be administered intratumorally (IT). Part A will enroll subjects with advanced/metastatic, recurrent, injectable solid tumors with emphasis on head and neck squamous cell cancer (HNSCC), triple negative breast cancer (TNBC), anaplastic thyroid carcinoma (ATC) and cutaneous squamous cell carcinoma (cSCC).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom
  • the Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital

    Glasgow, United Kingdom

  • Oxford University Hospitals Nhs Trust

    Headington, United Kingdom

  • the Royal Marsden Hospital

    London, United Kingdom

  • the Christie Nhs Foundation Trust

    Manchester, United Kingdom

United States
  • Honor Health

    Scottsdale, Arizona, United States

  • Columbia University/cumc

    New York, New York, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

  • Next Oncology

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CDK-002
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Sept 2020
Primary completion
3 Aug 2022
Completion
23 Dec 2022
Last update posted
8 Feb 2023
Registered enrollment
27
Registry id
NCT04592484
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.